NAGE Q3 2022 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-1.4% YoY

Gross Profit

$10M59.8% margin

Operating Income

-$3M-18.0% margin

Net Income

-$985,000-5.8% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$46M

Total Liabilities

$25M

Stockholders' Equity

$21M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$17M	-1.4%
Gross Profit	$10M	$11M	-3.5%
Operating Income	-$3M	-$9M	+65.3%
Net Income	-$985,000	-$9M	+88.9%